Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy.

[1]  H. Dombret,et al.  Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia , 2019, European journal of haematology.

[2]  H. Klepin.  Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice. , 2019, Hematology. American Society of Hematology. Education Program.

[3]  M. Liedtke,et al.  Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study , 2019, Cancer.

[4]  J. Esteve,et al.  The poor prognosis of low hypodiploidy in adults with B‐cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients , 2019, British journal of haematology.

[5]  I. Aldoss,et al.  Acute Lymphoblastic Leukemia in the Older Adult. , 2019, Journal of oncology practice.

[6]  R. Foà,et al.  Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia. , 2018, European journal of internal medicine.

[7]  J. Liesveld,et al.  Can we incorporate geriatric assessment in the management of acute lymphoblastic leukemia in older adults? , 2018, Journal of geriatric oncology.

[8]  H. Dombret,et al.  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.

[9]  H. Kantarjian,et al.  Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia , 2018, Current Hematologic Malignancy Reports.

[10]  A. Advani,et al.  Management of older adults with acute lymphoblastic leukemia: challenges & current approaches , 2018, International journal of hematologic oncology.

[11]  M. Konopleva,et al.  Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[12]  J. Liesveld,et al.  Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies. , 2017, Best practice & research. Clinical haematology.

[13]  M. Konopleva,et al.  Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial , 2017, JAMA oncology.

[14]  L. Ahlberg,et al.  Age but not Philadelphia positivity impairs outcome in older/elderly patients with acute lymphoblastic leukemia in Sweden , 2017, European journal of haematology.

[15]  H. Kantarjian,et al.  Treatment of acute lymphoblastic leukemia in older adults: now and the future. , 2017, Clinical advances in hematology & oncology : H&O.

[16]  M. Geyer,et al.  Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. , 2017, Blood.

[17]  W. Klapper,et al.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.

[18]  R. Larson,et al.  Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies , 2016, Cancer.

[19]  A. Fathi,et al.  The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies , 2016, Current Hematologic Malignancy Reports.

[20]  L. Escoda,et al.  Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. , 2016, Leukemia research.

[21]  V. Pullarkat.  Treatment of the older adult with ALL: An urgent call to action. , 2016, Leukemia research.

[22]  E. González-Barca,et al.  Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. , 2015, Journal of geriatric oncology.

[23]  E. Buss,et al.  Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL) , 2012 .

[24]  M. Tallman,et al.  Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial , 2012, British journal of haematology.

[25]  N. Gökbuget.  Treatment of Older Patients with Acute Lymphoblastic Leukaemia , 2017, Drugs & Aging.

[26]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.